Accepted for/Published in: JMIR Formative Research
Date Submitted: Dec 28, 2021
Open Peer Review Period: Dec 28, 2021 - Feb 22, 2022
Date Accepted: Dec 1, 2022
Date Submitted to PubMed: Dec 8, 2022
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Use of Inhaled Corticosteroids or Oral Steroids in a COVID-19 Telemedicine Cohort: Retrospective Chart Review
ABSTRACT
Background:
We identified patients with coronavirus disease 2019 that were followed by a telemedicine clinic and eventually referred to a post COVID clinic due to persistent symptoms of COVID-19. Of those patients requiring referral to the post COVID clinic, equal percentages of patients treated acutely with inhaled corticosteroids (ICS) and/ or oral steroids required referral to a pulmonary specialist.
Objective:
To determine if there was a difference in long term outcomes when prescribed ICS versus oral steroids
Methods:
Chart review comparing new prescription ICS to new prescription oral steroid
Results:
No difference in long term outcome between the groups
Conclusions:
It is safe to prescribe ICS or oral steroids for symptom relief, but cost may be an issue
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.